A method for preparing high-purity taurine and salt by reacting ethylene oxide with bisulfite to generate isethionate, performing an ammonolysis reaction on the isethionate in combination with ammonia and a metal salt, evaporating the reaction solution and subjecting the concentrated solution to ion exchange to obtain an adsorption solution, extracting taurine from the adsorption solution, eluting adsorbed metal cations from the ion exchange system by an acid, and separately collecting the eluate containing a salt.

A method for preparing high-purity taurine and salt by reacting ethylene oxide with bisulfite to generate isethionate, performing an ammonolysis reaction on the isethionate in combination with ammonia and a metal salt, evaporating the reaction solution and subjecting the concentrated solution to ion exchange to obtain an adsorption solution, extracting taurine from the adsorption solution, eluting adsorbed metal cations from the ion exchange system by an acid, and separately collecting the eluate containing a salt.

A sulfonic acid derivative, wherein the sulfonic acid derivative is represented by the following general formula (1):

R.sup.1COOCH.sub.2CH.sub.2CFHCF.sub.2SO.sub.3.sup.−M.sup.+  (1)

where: R.sup.1 represents a monovalent organic group having carbon number of 1 to 200, having at least one hydroxyl group and optionally having a substituent other than the hydroxyl group; and M.sup.+ represents a counter cation.

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The present disclosure relates to a method for recycling a taurine mother liquor, which includes: adding a base to the taurine mother liquor, heating to a first temperature, carrying out a hydrolysis reaction, removing ammonia produced, and evaporating and concentrating the ammonia-removed solution to obtain an alkali metal hydroxyethyl sulfonate solution. When applying the method provided by the present disclosure for the recycling of the taurine mother liquor, the taurine mother liquor can be further converted into the alkali metal hydroxyethyl sulfonate solution, impurities are removed from the obtained alkali metal hydroxyethyl sulfonate solution, the impurity-removed alkali metal hydroxyethyl sulfonate solution is concentrated and crystallized, and the alkali metal hydroxyethyl sulfonate is separated out. The method provided by the present disclosure is an efficient and simple method for recycling the taurine mother liquor, which is very easy to implement industrially and can effectively recycle the taurine mother liquor.

The present disclosure relates to a method for recycling a taurine mother liquor, which includes: adding a base to the taurine mother liquor, heating to a first temperature, carrying out a hydrolysis reaction, removing ammonia produced, and evaporating and concentrating the ammonia-removed solution to obtain an alkali metal hydroxyethyl sulfonate solution. When applying the method provided by the present disclosure for the recycling of the taurine mother liquor, the taurine mother liquor can be further converted into the alkali metal hydroxyethyl sulfonate solution, impurities are removed from the obtained alkali metal hydroxyethyl sulfonate solution, the impurity-removed alkali metal hydroxyethyl sulfonate solution is concentrated and crystallized, and the alkali metal hydroxyethyl sulfonate is separated out. The method provided by the present disclosure is an efficient and simple method for recycling the taurine mother liquor, which is very easy to implement industrially and can effectively recycle the taurine mother liquor.

The present disclosure provides a system for efficiently preparing taurine, including: a solution storage unit configured to store a solution containing alkali metal taurinate, the solution being prepared by an ethylene oxide process; an ion exchange unit including at least one ion exchange resin column each configured to be activated by a first activation manner or a second activation manner independently, the first activation manner using sulfurous acid for activation to obtain alkali metal bisulfate and taurine, and the second activation manner using sulfuric acid for activation to obtain alkali metal sulfate and taurine; and a dispensing unit connected to the solution storage unit and the ion exchange unit respectively, and configured to adjust an amount of a solution conveyed from the solution storage unit to each of the at least one ion exchange resin column in the ion exchange unit.

The present disclosure provides a system for efficiently preparing taurine, including: a solution storage unit configured to store a solution containing alkali metal taurinate, the solution being prepared by an ethylene oxide process; an ion exchange unit including at least one ion exchange resin column each configured to be activated by a first activation manner or a second activation manner independently, the first activation manner using sulfurous acid for activation to obtain alkali metal bisulfate and taurine, and the second activation manner using sulfuric acid for activation to obtain alkali metal sulfate and taurine; and a dispensing unit connected to the solution storage unit and the ion exchange unit respectively, and configured to adjust an amount of a solution conveyed from the solution storage unit to each of the at least one ion exchange resin column in the ion exchange unit.

Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.